Reality beat their plan and they're leaning in: recent realized upside surprise, response underway, drivers still live
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management recounts realized favorable surprise better than company expected, already responding, cause still running. Let's parse. Key candidates: AMPYRA revenues higher than expected due to delayed generic entry. Jim Frates: "with additional upside from AMPYRA. Today we are adjusting our financial expectations for 2018 to reflect increased revenues due to delayed generic entrance for AMPYRA, which has now occurred." "stronger-than-expected as generic entrants were delayed coming to market. We expect revenues from AMPYRA and FAMPYRA in the fourth quarter to be approximately $20 million. Due to the recent launch of generic competition in the United States, we expect our AMPYRA revenues will be substantially lower during 2019." So surprise: AMPYRA revenues higher than expected because generics delayed. But cause? Generic delay has now ended; generics launched. They expect Q4 ~20M, but 2019 substantially lower. So cause is not still running; it's a temporary delay that has reversed. Also response? They adjusted guidance upward, but not really leaning in; no response to extend. So NO. Other candidates: ARISTADA INITIO launch? They say "Following the launch of ARISTADA INITIO, we have seen an acceleration in the sequential growth of the two-month dose, which grew 26% and accounted for 15% of ARISTADA's volume in the third quarter." Is that better than expected? They don't explicitly say it exceeded company's own expectations. They say "The value proposition is resonating" and "encouraging trends." But no explicit "ahead of expectations." Also response: expanding sales force by ~50 reps in Q4. But is surprise stated? Not really. They say "based on opportunities we are identifying and encouraging trends." Not "better than we expected." So no. VIVITROL? No. ALKS 3831 enrollment completed ahead of schedule? "In April we completed enrollment of our second Phase III study, ENLIGHTEN-2... on track for topline results later in fourth quarter." That's ahead of schedule? They say "completed enrollment ahead of schedule" for ARISTADA study? Actually "This six-month study recently completed enrollment ahead of schedule and we're looking forward to sharing topline data in the first half of 2019." That's for ARISTADA vs INVEGA SUSTENNA study. Completed enrollment ahead of schedule.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| CW | Curtiss-Wright Corporation | Q1 2024 | 2024-05-02 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TENB · Q2 2021 → YESThe question is about whether management recounts something real that turned out better than expected, and they're already responding to it, with the cause still in effect. YES The transcript shows management describing the Alsid acquisition as delivering a realized favorable surprise: customers and prospects received the identity and user permission vulnerability assessment "well received" and it led to "outperformance of our earlier expectations from the business." This concerns a real operating event (customer adoption and platform uptake) that already happened and exceeded the company's own prior expectations. Management is visibly responding by accelerating investments: they plan to continue adding quota capacity in the second half (more than in the first half) and to invest in sales and marketing, explicitly tied to the strong performance and confidence in the business.
CYBR · Q3 2021 → YESThe question is: Does management recount that something REAL in the recent period turned out BETTER THAN THE COMPANY ITSELF HAD EXPECTED OR PLANNED — and is the company ALREADY responding to that favo...YES Management describes a realized favorable surprise in the subscription transition: "we made strong progress and outperformed our expectations in the third quarter" and "subscription ARR growth accelerated to 131%," with "strong demand for our SaaS solutions" continuing to drive it. They are already responding visibly by accelerating the transition and realloc resources, resetting plans upward to exit by Q3 2022 instead of Q4, and raising the annual recurring revenue growth expectation from 35% to 37% based on record bookings. The cause remains in effect, as they note the acceleration and strong demand environment persisting into the year.
ET · Q2 2023 → YESThe question is: Does management recount that something REAL in the recent period turned out BETTER THAN THE COMPANY ITSELF HAD EXPECTED OR PLANNED — and is the company ALREADY responding to that favo...YES The transcript shows management describing a realized favorable surprise on the Enable acquisition: actual performance "exceed[s] anything that we ever expected," with results "significantly higher, a good probably 40% or 50% higher than what we were anticipating." They attribute part of the upside to ongoing commercial synergies being discovered daily as integration proceeds. Management is visibly responding by integrating the assets, actively identifying and implementing new commercial opportunities (new routes, blending, additions to move more throughput), and reallocating attention toward expanding volumes.